Catalog No.: PC-35079Not For Human Use, Lab Use Only.
OBE022 (Ebopiprant, OBE-022) is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes.
OBE022 (Ebopiprant, OBE-022) is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes.
OBE022 inhibits spontaneous, oxytocin- and PGF2α-induced human myometrial contractions alone and is more effective in combination with atosiban or nifedipine.
OBE022 reduces spontaneous contractions in near-term pregnant rat, OBE022 delayed RU486-induced parturition and exerted synergistic effects in combination with nifedipine.
OBE022 exhibits potent tocolytic effects on human tissues ex vivo and animal models in vivo without causing the adverse fetal side effects.
